Background. The genus Norovirus comprises large genetic diversity, and new GII.4 variants emerge every 2-3 years. It is unknown in which host these new variants originate. Here we study whether prolonged shedders within the immunocompromised population could be a reservoir for newly emerging strains.
Noroviruses are rapidly evolving positive-stranded RNA viruses and are a predominant nonbacterial cause of acute gastroenteritis in all age groups worldwide [1] . The genus Norovirus demonstrates large genetic diversity and is divided into at least 7 genogroups and subdivided into >30 genotypes [2] . Noroviruses evolve through recombination and through accumulation of mutations leading to changes in epitopes targeted by protective antibodies (antigenic drift). Antigenic drift has been observed for several genotypes but is most prominent in the predominant lineage genogroup II, genotype 4 (GII.4), of which a new antigenic variant arises and typically replaces the previously established variant every 2-3 years [3] . In the last 2 decades, 6 distinct GII. 4 [4] . The evolution of norovirus GII.4 follows a stepwise or epochal pattern, with limited genetic diversity within variants and large genetic distance-up to 25 amino acid (aa) mutations (4.6%) in the 541-aa VP1 protein-between variants [5] . Most genetic variation occurs in the protruding (P) domain of the VP1 protein, which is exposed to the outer surface of the capsid and shown to contain blockade epitopes and the receptor-binding pocket [6] . The emergence of epidemic GII.4 variants has been associated with a significant increase in the number of outbreaks, leading to an increase in morbidities and mortality in risk groups, including children, elderly individuals, and immunocompromised patients, and related costs for society [7] [8] [9] .
Intermediate strains that fill the genetic gap between successive GII.4 variants are rarely detected, which raise questions on how and where these strains emerge. Noroviruses circulating in animal reservoirs have been suggested as a source of norovirus variation. Although some animal genotypes are relatively closely related to human genotypes, GII.4 strains are rarely found in animals, making zoonotic introduction an unlikely hypothesis for the observed pattern of evolution of GII.4 [10, 11] . Therefore, it is tempting to suggest that norovirus GII.4 diversity originates within the human population. The immunocompromised host is a potential reservoir for norovirus variants [12] . While norovirus infection is self-limiting in immunocompetent hosts, it is increasingly recognized that immunocompromised individuals can have prolonged symptoms and can shed noroviruses for up to years. The failure to clear the virus, coupled with high viral loads, may result in substantial sequence diversity in a patient with chronic infection [12] , but an important question is whether chronic norovirus shedders have sufficient (mucosal) immunity to drive selection of antigenic variants. Incidental evidence suggests changes in viruses over time in these patients, including aa changes in B-cell epitopes, but only a limited number of patients were assessed [13] [14] [15] .
In this study, we asked whether patients with chronic norovirus infection (ie, chronic shedders) could be a reservoir for genetically distinct variants. A selection of stool samples collected from 16 patients during a span of 6.5 years was subjected to deep sequencing to analyze norovirus evolution within patients over time.
METHODS

Study Population and Sample Selection
Sixty-five fecal samples from 16 immunocompromised patients were retrospectively selected from the Erasmus Medical Center biobank and screened for chronic infections. Solid organ transplant recipients with chronic norovirus infection were derived from an earlier study on the prevalence of chronic norovirus infection in a tertiary care hospital, and additional screening was performed for immunocompromised patients without solid-organ transplants [16] . For each patient, we selected the first and last known norovirus-positive sample as a minimum, as well as intermediary samples, depending on availability. All samples had been obtained for diagnostic purposes and tested positive for norovirus RNA by an in-house standard diagnostic reverse-transcription polymerase chain reaction (RT-PCR) assay with a cycle threshold of < 32. Samples were stored at −80°C freezer. The Erasmus Medical Center ethics committee approved the study under registration number MEC-2015-025.
Viral RNA Isolation
A clarified 10% (w/v) fecal suspension was prepared in phosphate-buffered saline, and viral RNA was extracted from 140 µL of the suspension, using the Qiamp viral RNA minikit (Qiagen, Hilden, Germany). The RNA extract (40 µL) was concentrated to 11 µL by a vacuum concentrator (Savant SpeedVac; ThermoFisher Scientific; Waltham, MA) and used for first-strand complementary DNA (cDNA) synthesis, using random hexamers and Superscript III reverse transcriptase (ThermoFisher Scientific). The resulting cDNA was used for double-stranded DNA synthesis, using the NEBNext messenger RNA Second Strand Synthesis Module (NEB, Ipswich, MA) according to the manufacturer's instructions. Double-stranded DNA was purified and concentrated with the Genomic DNA Clean and Concentrator kit (Zymo Research, Irvine, CA), with a final 30-µL elution. The DNA yield was quantified using a Qubit 2.0 fluorometer (Invitrogen, Carlsbad, CA).
Target Enrichment and Library Preparation for Next-Generation
Sequencing
Overlapping 120-mer RNA baits complementary to and spanning partial or complete reference genomes of 987 norovirus strains were designed by the PATHSEEK consortium [17] . The specificity of the baits was verified by a nucleotide search (using the Basic Local Alignment Search Tool [BLAST]) against the Human Genomic Plus Transcript database (National Center for Biotechnology Information). The custom-designed norovirus bait library was uploaded to E-array and synthesized by Agilent Technologies. Norovirus cDNA samples, supplemented optionally with carrier G147 human genomic DNA (Promega) to achieve 200 ng of DNA, were sheared for 120 seconds, using a Covaris E210 (with a duty cycle of 5%, a peak incident power of 4, and 100 cycles per burst). End-repair, nontemplated addition of a 3ʹ adapter ligation, hybridization, enrichment PCR, and all postreaction cleanup steps were performed according to the SureSelect Illumina Paired-End Sequencing Library XT protocol [17] . All recommended quality steps were performed between steps.
Illumina Sequencing
Libraries were multiplexed at 48 sample libraries per run. Pairedend 300-nucleotide sequencing was performed on an Illumina MiSeq sequencer, version 3, using the 600-cycle reaction kit. Base calling and sample demultiplexing were performed using the default settings on the MiSeq sequencer, generating paired FASTQ files for each sample.
De Novo Assembly and Identification of Viral Genomes
Raw sequencing reads were processed to remove adapters and trimmed from the 3ʹ end to reach a median Phred score of ≥35, using QUASR [18] . The reads were assembled into contigs by using de novo assembly with SPAdes 3.9.0 [19] . Calicivirusencoding contigs were identified with a modified SLIM algorithm combined with ublast [20, 21] . Partial but overlapping contigs were joined into full-length genome sequences, using Geneious v9.0.4 (Biomatters), and ambiguities were resolved by directly counting 21-nucleotide motifs containing the ambiguous site in the quality-controlled short-read data. The python script used to check ambiguous sites is available at Github (available at: https://github.com/mlcotten). Nucleotide-and aa-uncorrected maximum pairwise distances between consensus sequences were calculated using MEGA, version 7.0.18 [22] . Norovirus consensus sequences were submitted to GenBank (accession numbers MF140633-MF140697).
Minimum-Spanning Network and Maximum-Likelihood
Phylogenetic Trees
All de novo-assembled genomic sequences were aligned using AliView, version 1.16 [23] . To investigate the clustering patterns, a minimum-spanning network within and between patients was constructed in PopART, version 1.7 (available at: http:// popart.otago.ac.nz/index.shtml), with an epsilon of 0 [24] .
Maximum-likelihood phylogenetic trees were constructed in RAxML under a GTR-Γ model of substitutions with 500 bootstraps [25] . USEARCH, version 7.0 was used to select representative GII.4 reference background sequences, using a similarity cutoff of 98.6% [20] . The number of available GenBank reference sequences for GII.3, GII.6, and GII.7 was limited and therefore did not need to be reduced.
Minor Variant Analysis
For each sample. the quality-controlled short reads were mapped to the assembled genome, using BWA [26] . The resulting pileup file was parsed to identify positions with nonconsensus nucleotides. Only positions with a minimum coverage of 100 reads and only reads with minimum quality score of 35 were reported. Positions with >10% minor variant frequency were collected and graphed by genome position. While this threshold is relatively high, it was set to avoid overinterpretation of the data in view of contamination problems that have been reported for Illumina platform-based next-generating sequencing (available at: https://www.illumina.com/content/dam/illumina-marketing/ documents/products/whitepapers/index-hopping-white-paper-770-2017-004.pdf?linkId=36607862). Our future work aims to optimize lower-frequency-variant calling based on next-generation deep-sequencing applications for clinical decision making. The Python scripts used for the analysis and graphing are available at Github (available at: https://github.com/mlcotten).
RESULTS
Patient Profiling
Patients were sampled between 2008 and 2014, had an average age of 46 years (range, 3-72 years), and were infected with norovirus GII.P4-GII.4, GII.Pe-GII.4, GII.P7-GII.6, GII.P7-GII.7, or GII.P21-GII.3 (Table 1 ). Patients were immunocompromised due to solid-organ transplantation (8 patients received a kidney transplant, and 2 received a lung transplant), allogeneic stem cell transplantation (2 patients), leukemia (2 patients), or a As defined by the time between first and last sample.
b As reported in the hospital patient database and subjected to the interpretation of the clinician.
immunological disorders (2 patients). The average norovirus shedding time (at the end of the study period) was 352 days (range, 76-716 days).
Quality Control
For initial quality assessment, we compared the total number of reads, the number of norovirus-specific reads, and genome read depth for each sample in relation to the norovirus quantitative RT-PCR cycle threshold (Supplementary Figure 1A-C) . The median number of short reads per sample 311 558, with the majority of reads (median value, 91%) specific for norovirus. The median read depth of the full genomes was 4679. As expected given the use of a capture array, there was not a strong correlation between these 3 measures of sequencing performance and the input cycle threshold, with performance only dropping at the highest cycle thresholds. Four samples showed lower total reads and lower norovirus-specific reads (patient 4, on day 355; patient 10, on day 462; patient 11, on day 83; and patient 10, on day 508). Several samples (patient 4, on day 355; patient 9, on days 121 and 176; patient 10, on day 508; patient 12, at all 4 time points; and patient 16, on day 0) yielded >1 genome by use of de novo assembly, suggesting either coinfection or technical contamination. Coinfection with another genotype from the study was excluded on the basis of epidemiological data (sampling date) and clustering of samples in a minimum-spanning tree, and technical contamination was the most likely explanation for these secondary genomes, based on sequence batch number and genome coverage. To avoid overinterpretation of the data, low-coverage contigs were therefore removed from the analysis. As a measure of sample handling and quality control, a minimum-spanning tree of all 65 genomes was constructed (Figure 1 ). Genomes clustered closely by patient in nearly all cases, although one group of patients (patients 3, 4, and 10) was infected with related viruses that showed some overlap in the tree. Maximum-likelihood phylogenetic trees of full genomes and each of the 3 open reading frames (ORFs) were inferred (Supplementary Figure 2) , showing similar consistent patterns of patient-derived genomes.
Within-Host Genetic Evolution as Compared to Viral Genetic Diversity in the General Population
To study within-host virus evolution, ORF2 consensus sequences from chronically infected patients were compared to ORF2 
(48) (32) Figure 2 and GII.3, GII.6, and GII.7 are shown in Supplementary Figure 3A , 3B, and 3C, respectively). Ten of 13 GII.4-infected patients (76.9%) were infected with viruses similar to known GII.4 variant clusters (Figure 2 with non-GII.4 norovirus strains, were infected with strains with a large genetic distance from reference strains, but this can be explained in part by the availability of a limited number of reference sequences (Supplementary Figure 3A-C) .
Viral Mutation Rate and the Effect of Immune Status
Full genome consensus sequences were used to determine the within-patient average nucleotide and aa changes per day ( Figure 3A) . The nucleotide changes per day among individual patients showed variation from 0.03 to 0.37, and the aa changes per day ranged from 0.01 to 0.21, and although variation among individuals was high, no significant mutation rate differences were observed between immune status groups (ie, patients with solid-organ transplants, patients with stem cell transplants, patients with hematologic disease, or patients with other immunocompromising conditions). The positions of nucleotide changes across the norovirus genomes were examined. All nucleotide changes occurring during the entire observation period were plotted for each patient ( Figure 3B ). Changes were observed throughout the genome.
Mutation Hotspots in the P Domain of VP1
A structure of the norovirus GII.4 Sydney 2012 P domain has been generated previously [27] , and this model was used to locate within-host aa changes for each GII.4-infected patient individually (Figure 4) . The majority of the observed aa changes were on the predicted outer surface of the P domain complex, at or near epitopes A, D, and E. A few aa changes were located more deeply within the P domain structure: V385A for patient 3, V385I for patient 8, P305L for patient 9, R286K for patient 11, and L452I for patient 13. To further study the effect of within-host evolution on antigenic evolution and receptor specificity, aa positions for blockade epitopes A, D, and E, known for GII.4 [28] , were determined for 13 GII.4-infected patients over time ( Figure 5 ). The exact location of antigenic epitopes for genotypes GII.3, GII.6, and GII.7 are unknown, and therefore changes in the epitopes of the virus populations of patients 5, 7, and 12 were not determined. All patients had a virus population with at least 1 aa change in the antigenic epitopes during follow-up ( Figure  5 ). The insertion of epitope D position 394 is found in a highly variable loop region, located at the top of the P2 domain, and has been present in all GII.4 variants observed since Farmington Hills 2002 [29, 30] . Patient 16 was infected with a strain most related to GII.4 US 95/96 and therefore lacked this insertion in all specimens. Remarkably, patient 1 was infected with GII. 4 Apeldoorn 2007, which initially contained the insertion at position 394 but lost it by day 566. Consensus ORF2 sequences of virus populations were also inspected for within-host mutations of receptor binding pocket sites I, II, and III (aa 343-347, 374, and 442-443, respectively, for GII.4; aa 360-363, 389, and 452, respectively, for GII.6; aa 357-360, 386, and 450-451, respectively, for GII3; and aa 349-351, aa 378, and aa 446-447, respectively, for GII.7) [31] . None of the 16 patients contained a virus population that showed within-host aa changes in the receptor-binding pocket sites, and therefore none of the virus populations changed receptor specificity (data not shown).
Viral Nonconsensus Minor Variants
The minor variant diversity was plotted over time to study whether the minor variant diversity can be used as an indicator for chronic infection (Figure 6 ). Although the viral diversity was variable over time, the majority of the 16 patients showed increases in minor variant content over the observation period: 6 of 16 patients showed a consistent increase in the minor variant content, with each longitudinal sample having more variants than the previous sample, and 13 of 16 patients had a final time point with more variants than first time point. Six patients started with high variant content (≥40 sites with >10% minor variant content in patients 5, 7, 9, 12, 15, and 16), which may indicate that these patients were infected for some time before the initial sampling. Variation was observed throughout the genome, suggesting that the variation was a consequence of a random process and not due to accumulation of changes as a consequence of selective pressure on specific proteins (data not shown). Furthermore, the minor variant content should be interpreted with caution as several samples showed evidence of contamination (see the "Quality Control" subsection, above).
DISCUSSION
The aim of this study was to describe norovirus within-host evolution and diversity in chronically infected and immunosuppressed patients. We show that immunocompromised patients were initially infected by viruses that can be phylogenetically linked to strains found in the general population. However, over the observation time, the within-host virus populations evolved into virus populations that were genetically distinct with mutations across the genome, including the antigenic domains. Immunocompromised patients therefore contain a reservoir of viruses that are genetically and possibly antigenically distinct from viruses circulating in the general population. While similar observations have been reported for individuals or small patient groups, we show that all patients with chronic norovirus who we identified in our hospital had evidence of evolving viruses [12, 13, 15, [32] [33] [34] .
Three of the GII.4-infected immunocompromised patients (patients 9, 15, and 16) shed viruses with a large genetic distance from any norovirus available in public databases. These patients were likely infected some time (possibly years) before the initial time of sampling in this study or, alternatively, were infected by a strain transmitted from another immunocompromised patient (which was also not represented in the public database). For patient 16 , there was evidence of long-term unexplained symptoms of gastroenteritis before the initial sample was obtained, in June 2010. This patient was reported to have symptoms of gastroenteritis for the 6 previous years, and in agreement with this observation the sample from 2010 contained a virus strain most closely related to GII.4 US 95/96, which was predominantly detected by surveillance until 2002 [5] . Thus, it is possible that this patient was infected with the same strain for at least 6 years before the sampling in the current study. The VP1 sequence from the last available samples from patients 9, 15, and 16 were 94%, 95%, and 92% similar, respectively, to those of the closest known strains. There is not a strict distance criterion for new GII.4 variants, but currently recognized successive variants have nucleotide similarity of >95% [33, 35] . However, the novel variants found in this study do not justify a new name since they are not yet an epidemic strain in 2 geographic distinct regions [35] . It remains to be determined whether new virus variants found in immunocompromised patients are of risk for other patients or the general population. Transmission between immunocompromised patients has been reported earlier but only at an early stage of infection, up to 17 days after initial diagnosis [36, 37] . We have tried to retrospectively find transmission events in this study by linking epidemiological information (ie, sampling date and hospital ward) about positive samples from immunocompromised patients to positive samples obtained from other patients, but we have not yet found transmission events (data not shown). This can, however, be a result of undersampling of the hospital patient population and staff, as previously described [38] . It could also be that the viruses found in immunocompromised patients are highly adapted to their host and/or have a lower fitness due to the limited immune pressure and are therefore not easily transmitted to other humans. This could, in theory, mean that immunocompromised patients are only infectious in Red denotes within-host changes in amino acid residues that occurred between the first and last sample, and orange denotes deletions. The reference structure shows epitopes A, D, and E in yellow. Numbers above the protein models indicated patient identifiers. Dark gray and gray indicate both monomers that form the P domain dimer, and blue indicates a glycan structure that functions as the norovirus (co-)receptor. The PyMOL Molecular Graphics System, version 1.8 (Schrödinger), was used to localize amino acid residues.
an early stage of infection, when the virus still maintains features necessary for infection in immunocompetent hosts. A specific capture method was used to deep sequence the whole norovirus genome from clinical samples without additional amplification steps; these methods have been successfully implemented for other viruses and bacteria [17, [39] [40] [41] .
The method provided a high coverage across the full norovirus genome, allowing for minor variant analysis with high sensitivity, in addition to analysis of the full genomes.
The majority of patients had a viral population with an increasing minor variant content over time, and therefore we concluded that an increased minor variant content is an Sequence  Identifier  29 4  p1  E7800007_p1_d0  T  p1  E1300272_p1_d566  T  p1  E7800016_p1_d716  S  p2  p2  p3  p3  p3  p4  p4  p6  p6  p6  p8  p8  p8  p8  p9  p9  p9  p9  p10  p10  p10  p10  p10  p11  p11  E1300306_p11_d83  p11  p11  p13  p13  p13  p14  p14  p14  p15  p15  p15  p15  p15  p15  p15  p15  p15  p16  p16  p16  p16  p16 E1300296_p2_d0 indication for chronic infection, as suggested by others [12, 42] . Patients shedding viruses with a large genetic distance (patients 9, 15, and 16) also had a highly diverse variant content on day 0, which supports our conclusion that these patients were already infected some time before the initial sampling. Other patients already showed high diversity in the earliest samples or a more variable pattern over time, which might be explained by a missed norovirus infection, with the earliest sequenced sample actually obtained after an unknown period of virus evolution in the immunosuppressed patient, disease progression, or changes in immunosuppressive therapy. The technical contamination detected in some of the specimens, which is quite commonly observed with Illumina deep sequencing, is a limitation of the quasi-species analysis as presented in this study, but we have corrected for this as described in the "Methods" section. There is currently no registered antiviral therapy available for norovirus infection, and patients with dehydration or malnutrition caused by norovirus infection can only be treated with supportive treatment. It has been observed that a temporary pause in immunosuppressive therapy could allow transient immune system recovery and help clear the virus, but this should be done with great care since this entails a risk for organ rejection and is not an option for patients who are immunocompromised because of other causes [43] . In other studies, a limited number of infected immunocompromised patients received experimental enterally administered immunoglobulin therapy for chronic norovirus infection, with mixed success rates [44] [45] [46] . With the results of this study, we hypothesize that the success of immunoglobulin treatment depends on the antigenic distance between the within-host strain and the virus population circulating at the moment of immunoglobulin harvesting. Given the high within-host mutation rates as shown in this study, immunoglobulin treatment may only be successful when it is produced from plasma batches from local patients Figure 6 . Minor variant content. For each sample, the specific minor variant content was determined by mapping all quality-controlled reads to the final consensus genome from that sample (See Methods section). Only sites with >100 fold coverage and reads with Phred quality score of >35 were reported. Positions with non-consensus nucleotide at >10% frequency were graphed and the total number of positions with variants in each category are listed at the left of each panel.
recovering from infection due to similar viruses and administered in an early stage of infection. Future prospective studies are needed to address this issue.
The number of immunocompromised patients has largely increased in the last few decades because of an increase in the number of allogeneic transplantations. It was shown here that novel norovirus variants are developed in the immunocompromised host, and future prospective studies are needed to assess the risks of transmission of this new strains to other immunocompromised patients and the general population and subsequent consequences for hospital infection control guidelines. In view of the frequent reports of hospital-acquired norovirus infection and the potential consequences in patients at risk for chronic norovirus infection, low-threshold screening for infection should be considered in high-risk patient wards.
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